Literature DB >> 9706486

Characterization of human glioblastoma xenograft growth in athymic mice.

T Ozawa1, J Wang, L J Hu, K R Lamborn, A W Bollen, D F Deen.   

Abstract

UNLABELLED: BACKGROUND-MATERIALS-
METHODS: We initiated the studies reported in this paper to establish baseline growth data for tumors produced by several human brain tumor cell lines. Female athymic mice were injected with five established human glioblastoma cell lines subcutaneously. We optimized implantation conditions in SF-767 cells by evaluating tumor take and growth characteristics, and resulting growth data were compared to 2 other cell lines. RESULTS-
CONCLUSIONS: Three (SF-767, U-251 MG-NCI, and U-87 MG) of the 5 cell lines produced solid, ellipsoid tumors. For SF-767 cells, the best tumor growth parameters were achieved when 3.0 x 10(6) cells in 0.1 ml medium containing fetal calf serum were injected unilaterally. These conditions produced a high percentage of usable tumors (77.6%) that were detectable approximately 3 days after implantation and reached a size of 100 mm3 in 23 days. Comparison of several growth characteristics of the tumors produced by the 3 cell lines revealed that SF-767 tumors displayed the most uniform growth rates, the fastest doubling times, and the most uniform usable group of tumors (> 100 mm3). U-87 MG and U-251 MG-NCI had a similar histopathologic appearance while SF-767 had a different histology. Our results indicate that these 3 human glioblastoma cells produce flank tumors that exhibit decidedly different growth parameters. We are currently using all 3 of these human brain tumor xenograft models in other in vivo studies.

Entities:  

Mesh:

Year:  1998        PMID: 9706486

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  5 in total

1.  Detection of hypoxia in human brain tumor xenografts using a modified comet assay.

Authors:  Jingli Wang; Jack Klem; Jan B Wyrick; Tomoko Ozawa; Erin Cunningham; Jay Golinveaux; Max J Allen; Kathleen R Lamborn; Dennis F Deen
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

2.  Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts.

Authors:  Tomoko Ozawa; Sergei M Gryaznov; Lily J Hu; Krisztina Pongracz; Raquel A Santos; Andrew W Bollen; Kathleen R Lamborn; Dennis F Deen
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

3.  Epigenetic modulator inhibition overcomes temozolomide chemoresistance and antagonizes tumor recurrence of glioblastoma.

Authors:  Byoung-San Moon; Mingyang Cai; Grace Lee; Tong Zhao; Xiaofeng Song; Steven L Giannotta; Frank J Attenello; Min Yu; Wange Lu
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

4.  DNA fingerprinting of glioma cell lines and considerations on similarity measurements.

Authors:  Pierre Bady; Annie-Claire Diserens; Vincent Castella; Stefanie Kalt; Karl Heinimann; Marie-France Hamou; Mauro Delorenzi; Monika E Hegi
Journal:  Neuro Oncol       Date:  2012-05-08       Impact factor: 12.300

5.  Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype.

Authors:  Laura J Lewis-Tuffin; Fausto Rodriguez; Caterina Giannini; Bernd Scheithauer; Brian M Necela; Jann N Sarkaria; Panos Z Anastasiadis
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.